Cerevel Therapeutics Holdings Inc (CERE)

$41.77

-0.28

(-0.67%)

Market is closed - opens 7 PM, 22 May 2024

Insights on Cerevel Therapeutics Holdings Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.5% return, outperforming this stock by 35.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 232.5% return, outperforming this stock by 32.4%

Performance

  • $41.75
    $42.13
    $41.77
    downward going graph

    0.06%

    Downside

    Day's Volatility :0.91%

    Upside

    0.85%

    downward going graph
  • $19.59
    $43.59
    $41.77
    downward going graph

    53.1%

    Downside

    52 Weeks Volatility :55.06%

    Upside

    4.18%

    downward going graph

Returns

PeriodCerevel Therapeutics Holdings IncSector (Health Care)Index (Russel 2000)
3 Months
1.73%
-0.6%
0.0%
6 Months
71.61%
12.1%
0.0%
1 Year
22.85%
11.3%
0.0%
3 Years
190.07%
17.6%
-20.1%

Highlights

Market Capitalization
7.7B
Book Value
$3.1
Earnings Per Share (EPS)
-2.73
Wall Street Target Price
43.4
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-29.79%
Return On Equity TTM
-92.45%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-484.5M
Diluted Eps TTM
-2.73
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.59
EPS Estimate Next Year
-2.88
EPS Estimate Current Quarter
-0.61
EPS Estimate Next Quarter
-0.62

Analyst Recommendation

Buy
    68%Buy
    31%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Cerevel Therapeutics Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
5
5
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 3.9%

Current $41.77
Target $43.40

Technicals Summary

Sell

Neutral

Buy

Cerevel Therapeutics Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cerevel Therapeutics Holdings Inc
Cerevel Therapeutics Holdings Inc
-0.78%
71.61%
22.85%
190.07%
322.77%
Moderna, Inc.
Moderna, Inc.
37.56%
83.82%
13.37%
-12.47%
553.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
10.42%
24.29%
32.26%
98.6%
210.52%
Novo Nordisk A/s
Novo Nordisk A/s
7.9%
30.89%
58.53%
230.87%
458.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.52%
25.13%
30.01%
109.26%
156.43%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cerevel Therapeutics Holdings Inc
Cerevel Therapeutics Holdings Inc
NA
NA
NA
-2.59
-0.92
-0.3
NA
3.1
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.46
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.16
29.16
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.83
45.83
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.9
28.9
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cerevel Therapeutics Holdings Inc
Cerevel Therapeutics Holdings Inc
Buy
$7.7B
322.77%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.0B
553.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.8B
210.52%
29.16
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$592.1B
458.51%
45.83
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.1B
156.43%
28.9
39.46%

Institutional Holdings

  • Bain Capital Investors LLC

    36.05%
  • Perceptive Advisors LLC

    5.92%
  • FMR Inc

    5.32%
  • venBio Select Advisor LLC

    4.15%
  • Vanguard Group Inc

    4.10%
  • BlackRock Inc

    3.31%

Corporate Announcements

  • Cerevel Therapeutics Holdings Inc Earnings

    Cerevel Therapeutics Holdings Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

cerevel therapeutics is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (cns). the company has a portfolio of experimental neuroscience therapies, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of cns disorders, including parkinson’s, alzheimer’s, epilepsy, schizophrenia and addiction. headquartered in the greater boston area, cerevel was formed in 2018 through a partnership between bain capital and pfizer.

Organization
Cerevel Therapeutics Holdings Inc
Employees
355
CEO
Dr. N. Anthony Coles Jr., M.P.H.
Industry
Finance

FAQs